English
English
English
Single Injection Cancer Therapy Shows Breakthrough Results in Early Trial
New Delhi: Cancer immunotherapy has long been seen as a breakthrough in treatments, but results have often fallen short of expectations. Now, a new study suggests a redesigned approach could deliver stronger and more consistent outcomes.
Research published on March 16 2026, scientists tested a modified antibody that injected directly into a tumour and The early results were encouraging tumours shrank in half of the patients and two individuals experienced complete remission, meaning their cancer disappeared entirely.
The phase 1 trial involved 12 patients with advanced cancers including melanoma, kidney cancer, and aggressive breast cancer.But the treatment targeted only one tumour per patient, doctors noticed something unexpected.
Not only did the injected tumours shrink but also in some cases the tumours in other parts of the body also disappeared. This suggests the therapy may activate the immune system in a way that helps it attack cancer throughout the body.
“This kind of response in a small group is remarkable,” said by Juan Osorio from Memorial Sloan Kettering Cancer Center.
The therapy uses a redesigned CD40 agonist antibody called 2141-V11. Instead of delivering it through the bloodstream the researchers injected it directly into a tumour.
CD40 antibodies have been studied for years because they help activate immune cells. However, the earlier versions often caused serious side effects, including inflammation and liver damage.
In 2018, Jeffrey V. Ravetch and his team at Rockefeller University improved the design of the antibody. Their version boosts the immune response while reducing harmful side effects.By injecting the drug directly into the tumour, researchers were able to further limit toxicity and improve effectiveness.
In this study, Two patients showed dramatic results. One woman with melanoma had dozens of tumours in her leg and foot. After doctors injected just one tumour, all of them gradually disappeared.
Another patient with metastatic breast cancer saw tumours vanish from multiple organs, including the liver and lungs, even though only one tumour was treated.
These cases suggest the immune system, once activated, can travel through the body and attack cancer cells wherever they are.
Following these promising results the researchers have expanded that the trial to nearly 200 patients across institutions such as Duke University and Rockefeller University Scientists are now trying to understand why some patients respond better than others. Early findings suggest that people with stronger immune activity before treatment may have better outcomes.
While the results are exciting, the experts stress that this is still early research. The trial is small, and larger studies are needed to confirm how well the treatment works.
Still, the idea that a single injection could trigger a body-wide response is a major step forward. Researchers hope this approach could lead to safer and more effective treatments for the patients with advanced cancers.
For now, the findings offer cautious optimism and a glimpse into a new direction for cancer therapy.
